Proof-of-concept trial of intranasal epinephrine (G2B011)

Trial Profile

Proof-of-concept trial of intranasal epinephrine (G2B011)

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2014

At a glance

  • Drugs Epinephrine (Primary)
  • Indications Anaphylaxis
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors G2B Pharma; Shin Nippon Biomedical Laboratories
  • Most Recent Events

    • 13 Oct 2014 New trial record
    • 13 Aug 2014 Results published in G2B Pharma media release.
    • 13 Aug 2014 This proof-of-concept trial was successfully completed in 2013, according to a G2B Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top